DMPD Stock Overview
Manufactures and sells off-patent branded pharmaceutical products in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Dermapharm Holding SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €47.97 |
| 52 Week High | €47.97 |
| 52 Week Low | €36.74 |
| Beta | 1.14 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | 0.31% |
| 5 Year Change | 111.79% |
| Change since IPO | 70.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| DMPD | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 5.0% | 2.2% |
| 1Y | n/a | 2.5% | 8.8% |
Return vs Industry: Insufficient data to determine how DMPD performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how DMPD performed against the UK Market.
Price Volatility
| DMPD volatility | |
|---|---|
| DMPD Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: DMPD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DMPD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 3,404 | Hans-Georg Feldmeier | ir.dermapharm.de |
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription healthcare products, herbal extracts, and other pharmaceutical products.
Dermapharm Holding SE Fundamentals Summary
| DMPD fundamental statistics | |
|---|---|
| Market cap | €2.01b |
| Earnings (TTM) | €122.56m |
| Revenue (TTM) | €1.15b |
16.4x
P/E Ratio1.7x
P/S RatioIs DMPD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMPD income statement (TTM) | |
|---|---|
| Revenue | €1.15b |
| Cost of Revenue | €432.56m |
| Gross Profit | €718.65m |
| Other Expenses | €596.09m |
| Earnings | €122.56m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Nov 15, 2023
| Earnings per share (EPS) | 2.28 |
| Gross Margin | 62.43% |
| Net Profit Margin | 10.65% |
| Debt/Equity Ratio | 207.6% |
How did DMPD perform over the long term?
See historical performance and comparison